New therapeutic agents in the treatment of recurrent high-grade gliomas.

The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration. This article analyses the new drugs that have been introduced in the treatment of these patients in the latest years, the objective response, the time to progression and the mean survival time. The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years. New approaches to the chemotherapy treatment are necessary. Enrolment of patients into rigorous, well-conducted, clinical trials, both at tumour diagnosis and after tumour recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
AuthorsA A Brandes, L M Pasetto
JournalForum (Genoa, Italy) (Forum (Genova)) 2000 Apr-Jun Vol. 10 Issue 2 Pg. 121-31 ISSN: 1121-8142 [Print] ITALY
PMID10875974 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents (therapeutic use)
  • Brain Neoplasms (drug therapy)
  • Glioma (drug therapy)
  • Humans
  • Neoplasm Recurrence, Local (drug therapy)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: